Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

Trial Profile

A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Mavrilimumab (Primary) ; Golimumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms EARTH EXPLORER 2
  • Sponsors MedImmune
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Jan 2018 Results of pooled data assessing long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107) and open-label extension (OLE; NCT01712399), were published in the Arthritis and Rheumatology.
    • 12 Sep 2017 Results published in the Arthritis and Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top